Skip to Content
Merck
All Photos(1)

Key Documents

B7188

Sigma-Aldrich

Blonanserin

≥98% (HPLC)

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C23H30FN3
CAS Number:
Molecular Weight:
367.50
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

Quality Level

Assay

≥98% (HPLC)

form

powder

color

white to off-white

solubility

DMSO: ≥10 mg/mL

originator

Dainippon Sumitomo

storage temp.

room temp

SMILES string

CCN1CCN(CC1)c2cc(-c3ccc(F)cc3)c4CCCCCCc4n2

InChI

1S/C23H30FN3/c1-2-26-13-15-27(16-14-26)23-17-21(18-9-11-19(24)12-10-18)20-7-5-3-4-6-8-22(20)25-23/h9-12,17H,2-8,13-16H2,1H3

InChI key

XVGOZDAJGBALKS-UHFFFAOYSA-N

Biochem/physiol Actions

Blonanserin is a D2/5-HT2 receptor antagonist; atypical antipsychotic.

Features and Benefits

This compound was developed by Dainippon Sumitomo. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Precautionary Statements

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 4

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Blonanserin for the treatment of delirium patients at an emergency medical care center: an open-label study.
Koji Kato et al.
Asian journal of psychiatry, 6(2), 182-183 (2013-03-08)
Improvement in quetiapine-induced hypoglycemia following a switch to blonanserin.
Yutaro Suzuki et al.
Psychiatry and clinical neurosciences, 66(4), 370-371 (2012-05-26)
Atsushi Hamuro et al.
Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 10(4), 198-200 (2010-12-17)
The aim of the present study was to determine the efficacy, side-effects and tolerability of blonanserin for treating refractory behavioural psychological symptoms of dementia (BPSD). The present study was a 12-week, prospective, structured clinical trial of blonanserin for the treatment
Yu-Guan Wen et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 903, 46-52 (2012-07-24)
Blonanserin is a novel atypical antipsychotic with highly selective receptor antagonist activity to dopamine D₂ and 5-HT(2A). N-desethyl blonanserin (blonanserin C) is its major active metabolite in human plasma. Herein we report a new highly sensitive, selective, and rapid liquid
Tadashi Ogawa et al.
Analytical sciences : the international journal of the Japan Society for Analytical Chemistry, 26(10), 1099-1102 (2010-10-19)
A rapid and sensitive method for analysis of blonanserin in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry is presented. After pretreatment of a plasma sample by solid-phase extraction, blonanserin was analyzed by the system with a C(18) column. This

Articles

We offer many products related to serotonin receptors for your research needs.

We offer many products related to serotonin receptors for your research needs.

We offer many products related to serotonin receptors for your research needs.

We offer many products related to serotonin receptors for your research needs.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service